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The present studies were performed to determine sub-
type-specific roles of mitogen-activated protein kinase
in chondrogenesis. Erk-1/2 activities, downstream of
protein kinase C, decreased as chondrogenesis pro-
ceeded, whereas p38 activities, independent of protein
kinase C, continuously increased during chondrogene-
sis. Inhibition of Erk-1/2 with PD98059 enhanced chon-
drogenesis up to 1.7-fold, whereas inhibition of p38 with
SB203580 reduced it to about 30% of the control level.
Inhibition of Erk-1/2 or p38 did not affect precartilage
condensation. However, cartilage nodule formation was
significantly blocked by the inhibition of p38, whereas
Erk-1/2 inhibition did not affect it. Modulation of chon-
drogenesis by the inhibition of Erk-1/2 and p38 was ac-
companied by altered expression of adhesion molecules
in an opposite way. Expression of N-cadherin was re-
duced as chondrogenesis proceeded. Inhibition of p38
caused sustained expression of N-cadherin, whereas
Erk-1/2 inhibition accelerated the reduction of N-cad-
herin expression. Expression of integrin a5b1 and fi-
bronectin were found to transiently increase during
chondrogenesis. Inhibition of p38 caused continuous in-
crease of expression of these molecules, whereas Erk-1/2
inhibition accelerated the decrease of expression of
these molecules at a later period of chondrogenesis. Be-
cause temporal expression of these adhesion molecules
regulates chondrogenesis, the above results indicate
that Erk-1/2 and p38 conversely regulate chondrogene-
sis at post-precartilage condensation stages by modulat-
ing expression of adhesion molecules.
Formation of cartilage is initiated by differentiation of mesen-
chymes into chondrocytes. The differentiation process requires pro-
liferation of chondrogenic competent cells that subsequently un-
dergo precartilage condensation (1–3). Precartilage condensation is
characterized by cells that are more densely packed in specific
regions. This precartilage condensation is an important prerequi-
site for the initiation of chondrogenesis in mesenchymes in vivo. It
becomes evident that several adhesion molecules including cad-
herins (4–7), integrins (8, 9), and extracellular matrix (ECM)1
components (9–12) regulate precartilage condensation. Limb mes-
enchymes undergo spontaneous differentiation to chondrocytes in
vitro when cultured at a high seeding density such as micromass
culture in the presence of serum. Precartilage condensation similar
to that formed in vivo during chondrogenesis occurs in micromass
cultures of limb mesenchymes (13). The cellular aggregates that
form in early micromass cultures subsequently differentiate into
cartilage nodules, which express cartilage-specific molecules such
as type II collagen (6, 14–16). However, the signal transduction
pathways involved in precartilage condensation and initiated by
condensation are not well characterized.
We have previously shown that protein kinase C (PKC) pos-
itively regulates chondrogenesis of mesenchymes (17, 18). PKC
is a multigene family composed of 11 known isoforms (19, 20).
Multiple PKC isoforms such as a, e, z, and l/i were expressed in
chick limb mesenchymes. Among these, an increase in expres-
sion level and translocation from cytosol to the particulate
membrane fractions was most evident in PKC a, suggesting an
important role for PKC a in the regulation of chondrogenesis.
PKC regulated both proliferation of chondrogenic competent
cells and expression of cell adhesion molecules involved in
precartilage condensation. PKC-induced regulation of expres-
sions of cell adhesion molecules such as N-cadherin, fibronec-
tin, and its receptor a5b1 integrin appeared to be exerted via
signaling through the mitogen-activated protein (MAP) kinase
subtype, Erk-1/2 (18).
MAP kinases play a key role in a variety of cellular responses
including proliferation, differentiation, and apoptosis of cells.
Several parallel MAP kinase signaling pathways have been
defined in mammalian cells (21–23). The major MAP kinase
subtypes include Erk-1 and -2, c-Jun N-terminal kinase or
stress-activated protein kinase, and p38 MAP kinase. Individ-
ual MAP kinase subtypes appear to have equivalent but dis-
tinct upstream kinases that are activated by a wide variety of
extracellular stimuli. Some extracellular stimuli appear to ac-
tivate multiple MAP kinase pathways, whereas other signals
activate single MAP kinase pathway (21–23).
Our previous study indicated that Erks-1/2 are key signaling
molecules in PKC regulation of micromass culture-induced
chondrogenesis (18). Because MAP kinase subtypes regulate
cellular functions either cooperatively or antagonistically in
many cases (24–26), we investigated subtype-specific functions
of MAP kinases in the regulation of chondrogenic differentia-
tion of mesenchymes. Here, we report that p38 and Erk-1/2 act
as positive and negative regulators of chondrogenesis, respec-
tively, by conversely regulating expression of cell adhesion
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molecules including N-cadherin, fibronectin, and its receptor
a5b1 integrin at post-precartilage condensation stage.
EXPERIMENTAL PROCEDURES
Micromass Culture of Mesenchymes—Mesenchymes were derived
from the distal tips of Hamburger-Hamilton stage 23/24 embryo limb
buds (27) of fertilized White Leghorn chicken eggs as described previ-
ously (18). The cells were suspended at a density of 2.0 3 107 cells/ml in
Ham’s F-12 medium containing 10% fetal calf serum, and chondrogen-
esis was induced by adding the cells in 15-ml drops to culture dishes.
The cells were incubated for 2 h at 37 °C to allow attachment and
maintained in Ham’s F-12 medium containing 10% fetal calf serum, 50
mg/ml streptomycin, and 50 units/ml penicillin either in the absence or
presence of various reagents as described in each experiment. Chon-
drogenesis was determined by examining the expression of type II
collagen as described below and quantitated by staining sulfated carti-
lage matrix with Alcian blue. Briefly, micromass-cultured cells were
stained with Alcian blue; Alcian blue bound to sulfated glycosaminogly-
cans was extracted with 4 M guanidine-HCl and quantitated by meas-
uring absorbance at 600 nm.
Immunocytochemical Detection of Type II Collagen Expression and
Peanut Agglutinin (PNA) Binding—Differentiating mesenchymes were
fixed with 3% paraformaldehyde in phosphate-buffered saline for 10
min at room temperature. The cells were washed and incubated for 1 h
with anti-collagen type II monoclonal antibody (Developmental Studies
Hybridoma Bank, University of Iowa, Iowa City, IA) or 100 mg/ml of
biotinylated PNA (Vector Laboratories Inc., Burlingame, CA). Type II
collagen and PNA binding were visualized by developing with VEC-
TASTAIN ABC and DAB substrate solution kits (Vector Laboratories
Inc.) according to the procedure recommended by the manufacturer
(18).
Cell Proliferation Assay—Proliferation of mesenchymes during mi-
cromass culture was determined by direct counting of viable cells as
described previously (18). Briefly, mesenchymes were micromass-cul-
tured (3 spots/35-mm dish) in the absence or presence of various re-
agents for the indicated time periods. Individual cells were suspended
with 0.1% of trypsin and collagenase, and the number of viable cells was
counted in triplicate using a hemocytometer.
Cell Fractionation—Cytosolic and particulate membrane fractions
were prepared as described previously (18, 28). Briefly, cells micromass-
cultured for indicated periods were scraped in buffer A containing 20
mM Tris-HCl, pH 7.5, 0.25 M sucrose, 2 mM EGTA, and 2 mM EDTA
supplemented with inhibitors of protease and phosphatase (18, 28). The
cells were sonicated twice for 6 s and centrifuged at 100,000 3 g for 1 h.
The supernatant was designated as cytosolic fraction. The pellet was
extracted with buffer B containing 20 mM Tris-HCl, pH 7.5, 1% sodium
dodecyl sulfate (SDS), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, and
protease inhibitors. Following centrifugation at 15,000 3 g for 15 min,
the supernatant was saved as the particulate membrane fraction.
Western Blot Analysis—Total cell lysate was prepared from cells
micromass-cultured for various periods by extracting proteins with a
lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1%
Nonidet P-40, and 0.1% SDS supplemented with protease inhibitors.
Proteins were separated by polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes. The nitrocellulose sheet was
blocked with 3% nonfat dry milk in Tris-buffered saline. PKC isoforms
were detected with isoform-specific anti-PKC monoclonal antibodies for
e and l/i (Transduction Laboratories, Lexington, KY) or with polyclonal
antibodies for a and z (Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Expression of adhesion molecules was determined by using antibodies
purchased from the following sources: rabbit anti-chick N-cadherin
polyclonal antibody from Sigma, rabbit anti-human fibronectin poly-
clonal antibody from Upstate Biotechnology Inc. (Lake Placid, NY),
mouse anti-chick integrin a5 monoclonal antibody from Developmental
Studies Hybridoma Bank (University of Iowa, Iowa City, IA), and rabbit
anti-human integrin b1 polyclonal antibody from Chemicon (Temecula,
CA). The blots were developed using a peroxidase-conjugated secondary
antibody, and proteins were visualized by the ECL system.
Determination of Erk Activation—Mesenchymes were micromass-
cultured in the absence or presence of various reagents for the indicated
time periods. Proteins were extracted with a buffer containing 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, and
inhibitors of proteases and phosphatases. Expression of Erk-1/2 was
determined by Western blotting using antibodies obtained from Santa
Cruz Biotechnology Inc., and its activation was examined by Western
blotting using antibody specific to activated Erk-1/2 (New England
Biolabs, Beverly, MA) as described previously (18, 29).
p38 Kinase Assay—Activity of p38 was determined by immunocom-
plex kinase assay. Briefly, cell lysates were prepared in a lysis buffer
containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glyc-
erolphosphate, and inhibitors of proteases and phosphatases. The sam-
ples were precipitated with rabbit polyclonal anti-p38 antibody (Santa
Cruz Biotechnology Inc.). Immunocomplexes were collected by binding
to protein A-agarose beads (Pierce). After washing with lysis buffer, the
beads were resuspended in 50 ml of kinase reaction buffer containing 25
mM Tris-HCl, pH 7.5, 5 mM b-glycerolphosphate, 2 mM dithiothreitol,
0.1 mM sodium orthovanadate, 10 mM MgCl2, [g-
32P]ATP, and 2 mg of
ATF-2 fusion protein as a substrate for p38 (New England Biolabs).
Following incubation for 30 min at 30 °C, the reaction was stopped by
the addition of 43 Laemmli’s sample buffer followed by boiling. Sam-
ples were resolved by electrophoresis, and then phosphorylation of
ATF-2 was determined by autoradiography.
RESULTS
MAP Kinase Activities during Chondrogenesis of Mesen-
chymes—To determine subtype-specific functions of MAP ki-
nases, we first examined their activities and changes during
spontaneous chondrogenesis of mesenchymes initiated by mi-
cromass culture. Activation of Erk-1 and -2 was determined by
Western blotting with antibody that recognized activated Erk-
1/2. Because Erk-1 is a major Erk isoform and the phosphoryl-
ation pattern of Erk-2 is very similar to that of Erk-1 in chick
mesenchymes (18), we showed results of only Erk-1 in this
study. Phosphorylation levels of Erk-1 were high at 1-day-old
culture and decreased as chondrogenesis proceeded (Fig. 1A,
upper panel). The addition of 5 mM PD98059, a specific inhibitor
of MAP kinase kinase (30), to the culture significantly blocked
Erk-1 activation. However, the addition of 10 mM SB203580, a
specific inhibitor of p38 MAP kinase (31), to the culture did not
affect the decrease in Erk-1/2 activities. SB203580 also did not
affect PD98059-induced inhibition of Erk-1 phosphorylation.
FIG. 1. Activities of MAP kinase subtypes during chondrogen-
esis of mesenchymes. A, mesenchymes were micromass-cultured for
the indicated period in the presence of vehicle alone (CON), 5 mM
PD98059 (PD), and/or 10 mM SB203580 (SB). Activation of Erk-1 was
determined by Western blotting using antibodies specific to activated
Erk-1 (upper panel, pErk-1). Expression of Erk-1 in day 3 cultures was
determined by Western blotting (middle panel, Erk-1). Phosphorylation
level of Erk-1 at day 3 was quantitated by densitometry (n 5 4) (lower
panel). B, activity of p38 was determined by immuncomplex kinase
assay using ATF-2 as a substrate in mesenchymes micromass-cultured
for the indicated period in the absence or presence of 5 mM PD98059
and/or 10 mM SB203580 (upper panel, p-ATF2). Expression of p38 was
determined by Western blotting (middle panel, p38). Relative amount
of phosphorylated ATF-2 was quantitated by densitometry (n 5 3)
(lower panel).
Opposing Role of Erk and p38 in Chondrogenesis5614
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on D
ecem
ber 25, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Expression levels of Erk-1 remained constant in cells treated
with PD98059 and/or SB203580 at 3-day culture (Fig. 1A,
middle panel) or throughout the culture period (data not
shown).
Activity of p38 was very low at 1-day culture times; however,
it dramatically increased as chondrogenesis proceeded (Fig. 1B,
upper panel). Treatment of cells with SB203580 significantly
blocked p38 activity to about 10% of control level. Activity of
p38 was not affected by inhibition of Erk-1/2 with PD98059.
Also, the addition of PD98059 to the cells pretreated with
SB203580 did not significantly affect SB203580-induced inhi-
bition of p38 activity (Fig. 1B, upper panel). In contrast to the
change in activities, expression of p38 did not change during
chondrogenesis in cells treated with PD98059 and/or SB203580
(Fig. 1B, middle panel). Thus, Erk-1/2 and p38 activities are
oppositely regulated during chondrogenesis, and it is not likely
that Erk-1/2 and p38 directly cross-talk to regulate each other’s
activities.
Opposing Roles of p38 and Erk-1/2 in Chondrogenesis—To
determine whether the conversely regulated activities of Erk-
1/2 and p38 have differential roles in chondrogenesis, chondro-
genic differentiation was confirmed in control culture by exam-
ining cartilage-specific type II collagen expression (Fig. 2A).
When Erk-1/2 was inhibited by PD98059, expression of type II
collagen was significantly enhanced, to the extent of covering a
whole area of individual spots (Fig. 2A). Alcian blue staining of
sulfated proteoglycans revealed that chondrogenesis was en-
hanced up to 1.7-fold in a dose-dependent manner (Fig. 2, B
and C). In contrast to the effects of Erk-1/2 inhibition, however,
inhibition of p38 with SB203580 (10 mM) significantly blocked
expression of type II collagen. Type II collagen expression was
restricted to cartilage nodules whose numbers were signifi-
cantly reduced compared with control culture (Fig. 2A). The
degree of chondrogenesis in SB203580-treated cells was about
30% of the control, and the effect of SB203580 was dose-de-
pendent as quantitated by Alcian blue staining (Fig. 2, B and
C). The functional role of p38 in chondrogenesis was further
supported by the observation that PD169316, another potent
inhibitor of this kinase (32), inhibited chondrogenesis in a
dose-dependent manner (data not shown). Taken together, the
above results indicated that Erk-1/2 and p38 acted as negative
and positive regulators of chondrogenesis, respectively, during
in vitro micromass culture.
The inhibitory effect of SB203580 on chondrogenesis was
abolished by the inhibition of Erk-1/2 with PD98059 at low
concentrations of SB203580 (i.e. 2.5 and 5 mM). However, at
high concentrations of SB203580 (i.e. 10 and 20 mM), Erk-1/2
inhibition did not completely promote recovery of chondrogen-
esis that was blocked by p38 inhibition (Fig. 3). The degree of
chondrogenesis was 41 6 4 and 29 6 4% at 10 and 20 mM of
SB203580, and inhibition of Erk-1/2 induced differentiation by
51 6 4 and 35 6 3%, respectively. Therefore, although inhibi-
tion of Erk-1/2 enhanced chondrogenic differentiation in the
presence of p38 activity, Erk-1/2 inhibition appeared to be
insufficient to induce chondrogenesis in the absence of p38
activity.
p38 and Erk-1/2 Do Not Regulate Proliferation of Chondro-
genic Competent Cells—Because many extracellular molecules
known to regulate chondrogenesis exert their effects at the
stages of cell proliferation and/or precartilage condensation (5,
7, 33–36), we first examined whether the opposing roles of p38
and Erk-1/2 in the regulation of chondrogenesis were due to
converse regulation of cell proliferation. As shown in Fig. 4,
although chondrogenesis was significantly enhanced (Fig. 2),
inhibition of Erk-1/2 did not affect proliferation of chondrogenic
competent cells as determined by direct cell counting. Simi-
larly, inhibition of p38 with SB203580 to block chondrogenesis
up to about 30% of the control level (Fig. 2), also did not affect
proliferation of the cells (Fig. 4). This indicated that negative
and positive effects on chondrogenesis by the inhibition of p38
and Erk-1/2, respectively, were not brought about by modulat-
FIG. 2. Opposing roles of Erk-1/2 and p38 in the regulation of
chondrogenesis of mesenchymes. A, expression of type II collagen
was determined by immunocytochemistry in cells cultured for 4 days in
the presence of vehicle alone as a control, 5 mM PD98059, or 10 mM
SB203580. B and C, mesenchymes were micromass-cultured for the
indicated time periods in the presence of vehicle alone as a control, 5 mM
PD98059, or 10 mM SB203580 (B). Alternatively, cells were cultured for
4 days in the presence of various concentrations of PD98059 or
SB203580 (C). Chondrogenesis was quantitated by staining sulfated
proteoglycan with Alcian blue and measuring absorbance of bound
Alcian blue extract at 600 nm. The data represent averages of six
independent experiments with standard deviation.
FIG. 3. Inhibition of Erk-1/2 was not sufficient to induce chon-
drogenesis in the absence of p38 activity. Mesenchymes were mi-
cromass-cultured in the presence of vehicle alone or various concentra-
tions of SB203580 and 5 mM PD98059 for 4 days, and chondrogenesis
was quantitated by measuring absorbance of Alcian blue extract. The
data represent relative values of absorbance of Alcian blue extract
against the control and average values of five independent experiments
with standard deviation.
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ing proliferation of chondrogenic competent cells.
p38 Activity Is Required for the Progression of Precartilage
Condensation to Cartilage Nodules—We next examined the
question of whether Erk-1/2 and p38 regulated chondrogenesis
by modulating precartilage condensation or by affecting cellu-
lar events initiated by precartilage condensation. Precartilage
condensation was verified by staining cells with PNA, a specific
marker of precartilage condensation. PNA bound cell aggre-
gates or precartilage condensation before the deposition of car-
tilage-specific ECM components, making it possible to distin-
guish between precartilage condensation and differentiated
cartilage nodules (11, 13). On day 2 culture, numerous precar-
tilage condensations or aggregates were present (Fig. 5), which
were not differentiated to cartilage nodules as seen by the
absence of Alcian blue staining (Fig. 5). The cell aggregates
became large (Fig. 5) and differentiated to cartilage nodules on
day 4 culture that were stained by Alcian blue (Fig. 5).
Inhibition of Erk-1/2 with PD98059 did not significantly
affect precartilage condensation on 2-day-old culture. The size
and number of cartilage nodules on 4-day-old culture were also
not affected by the inhibition of Erk-1/2 (Fig. 5). However,
Alcian blue staining was significantly enhanced when Erk-1/2
was inhibited with PD98059 (Fig. 5), suggesting that inhibition
of Erk-1/2 enhanced expression of cartilage-specific molecules
including type II collagen and sulfated glycosaminoglycans, but
not by direct modulation of morphological changes such as
precartilage cartilage condensation and cartilage nodule for-
mation. Similar to the effects of Erk-1/2 inhibition, inhibition of
p38 with SB203580 did not affect precartilage condensation on
day 2 culture (Fig. 5). However, coalescence of cellular aggre-
gates and differentiation to cartilage nodules on day 4 culture
were significantly blocked in cells treated with SB203580 (Fig.
5). Therefore, p38 activity appeared to be required for the
cellular events involved in progression of precartilage conden-
sation to the cartilage nodule.
Opposite Regulation of the Expression of Adhesion Molecules
by Erk-1/2 and p38—Precartilage condensation as well as its
progression to cartilage nodules requires a regulated expres-
sion of cell adhesion molecules and ECM components (4, 8–11,
15). Therefore, the roles of the MAP kinase subtypes in the
expression of cell adhesion molecules and ECM components
were examined. Expression of N-cadherin was high in 1-day-
old culture and was reduced as chondrogenesis proceeded (Fig.
6). However, the inhibition of p38 with SB203580 induced
sustained expression of N-cadherin throughout the culture pe-
riod, whereas the inhibition of Erk-1/2 accelerated the decrease
of N-cadherin expression at the later periods of micromass
culture (Fig. 6). This indicated that p38 and Erk-1/2 activities
had opposing effects on N-cadherin expression during
chondrogenesis.
Similar to converse regulation of N-cadherin expression, the
expressions of fibronectin and its receptor integrin a5b1 were
also conversely regulated by p38 and Erk-1/2. The expression of
integrins a5 and b1 and fibronectin was increased transiently
during chondrogenesis; their expression was detected in cells
cultured for 1 day, increased as chondrogenesis proceeded, and
decreased thereafter at the later stages of chondrogenic differ-
entiation, i.e. the fifth day of culture (Fig. 6). Inhibition of
Erk-1/2 or p38 did not significantly change expression patterns
of these molecules at early periods of micromass culture, i.e.
from 1 to 3-day-old cultures. However, the inhibition of Erk-1/2
accelerated the decrease of integrin a5 and b1 and fibronectin
expression in the fourth and fifth day cultures, whereas the
inhibition of p38 caused continuous increase of expression of
integrins a5 and b1 throughout the culture period (Fig. 6).
Because a reduction of N-cadherin, integrin a5b1, and fibronec-
tin expression is necessary for chondrogenesis to progress after
cell condensation (4, 8–10), the above results indicated that a
balance of activities between p38 and Erk-1/2 appeared to
regulate expression of these adhesion molecules at later peri-
ods of micromass culture.
Erks-1/2 Are Downstream of PKC Signaling, Whereas p38 Is
Independent of PKC—Because our previous results indicated
that PKC regulated chondrogenesis by acting upstream of Erk-
1/2 (18), we next explored the possibility that p38 signaling was
also linked to the PKC signaling pathway. Among the PKC
isoforms such as a, e, z, and l/i expressed in differentiating
mesenchymes, expression of PKC a, and less dramatically so
PKC e, increased as chondrogenesis proceeded, whereas the
expressions of PKC z and l/i did not vary significantly during
chondrogenesis (Fig. 7A). Activation of PKC isoforms, as deter-
mined by examining translocation of cytosolic PKC to the par-
ticulate membrane fractions, was most evident in PKC a. The
level of PKC e also increased slightly, whereas levels of PKC z
and l/i decreased slightly in the particulate membrane fraction
during chondrogenesis. The amounts and expression patterns
of the expressed PKC isoforms were essentially the same
among cells cultured in the absence or presence of SB203580 or
PD98059 (Fig. 7). Similarly, distribution of expressed PKC
isoforms between cytosolic and particulate membrane fractions
was not affected by the inhibition of Erk-1/2 or p38 (Fig. 7),
indicating that the converse regulation of chondrogenesis by
p38 and Erk-1/2 was exerted by modulating neither expression
nor activation of PKC isoforms. Finally, we explored a possi-
bility that p38 in addition to Erk-1/2 was a downstream target
of PKC during chondrogenesis. Inhibition of PKC with Go6976
or down-regulation of PKC with prolonged treatment of cells
with phorbol 12-myristate 13-acetate resulted in an increased
phosphorylation of Erk-1 and inhibition of chondrogenesis (Fig.
8); however, neither inhibition of PKC with Go6976 nor down-
regulation with phorbol 12-myristate 13-acetate affected p38
activity during micromass culture (Fig. 8). Therefore, the re-
sults indicated that, unlike Erk-1/2, p38 was not linked to the
PKC signaling pathway.
DISCUSSION
Converse Regulation of Erk-1/2 and p38 Activities and Their
Opposing Roles in Chondrogenesis—The MAP kinase subtypes
Erk-1/2 and p38 are thought to play a key role in the signaling
processes of many types of cellular differentiation. For exam-
ple, it has been found that the activation of Erk-1/2 is required
for the differentiation of fibroblasts to adipocytes (37), whereas
inactivation of Erk-1/2 is required for C2C12 myoblasts to
initiate myogenesis (38). Several recent studies also indicated
FIG. 4. Modulation of Erk-1/2 and p38 did not affect prolifera-
tion of chondrogenic competent cells. The number of cells was
counted after micromass culture for the indicated time periods in the
presence of vehicle alone as a control, 5 mM PD98059, or 10 mM
SB203580. The data represent the percent increase in cell number
against day 1 culture and average values of five independent experi-
ments with standard deviation.
Opposing Role of Erk and p38 in Chondrogenesis5616
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on D
ecem
ber 25, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
that p38 regulates cellular differentiation; for instance, the
activation of p38 is required for erythroid differentiation (39),
neuronal differentiation in PC12 cells (40), and adipogenesis of
3T3-L1 cells (41).
In this study, we show that activities of the MAP kinase
subtypes, Erk-1/2 and p38, are conversely regulated during
chondrogenic differentiation of chick limb bud mesenchymes
induced by micromass culture (Fig. 1). We also demonstrate, by
using specific inhibitors of the MAP kinase subtypes, that an
increase of p38 activity is necessary for the progression of
precartilage condensation to cartilage nodule (Fig. 5). A de-
crease in Erk-1/2 activities is also required for the progression
of chondrogenesis, because inhibition of Erk-1/2 enhances
chondrogenesis (Fig. 2) and activation of Erk-1/2 by the inhi-
bition or down-regulation of PKC block chondrogenesis (18). On
the other hand, phosphorylation of another major MAP kinase
subtype, c-Jun N-terminal kinase, is not detected throughout
chondrogenic differentiation (data not shown). The inhibitors
used in this study, PD98059 and SB203580, are highly specific,
and they have no inhibitory activity on all other kinases tested
in vitro, including other MAP kinases at concentrations
far greater than the concentration used in the present work
(28, 29).
Our current results clearly indicated that both the decrease
in Erk-1/2 and the increase in p38 activities during micromass
culture are necessary for chondrogenic differentiation of mes-
enchymes. The stimulatory effect of Erk-1/2 inhibition on dif-
ferentiation is most evident in the presence of p38 activity (i.e.
in the absence or low concentration of SB203580), whereas
inhibition of Erk-1/2 in the absence of p38 activity (i.e. at high
concentration of SB203580) is not sufficient to induce chondro-
genesis although it slightly increases differentiation (Fig. 3).
Inhibition of p38 activity with SB203580, in the presence of
Erk-1/2 activities, is sufficient to block chondrogenesis (Fig. 2).
However, stimulation of Erk-1/2 by the inhibition or down-
regulation of PKC, even in the presence of p38 activity, is
sufficient to block chondrogenesis (Fig. 8). Therefore, oppo-
sitely regulated activities of both Erk-1/2 and p38 are essential
for the induction of chondrogenic differentiation.
Currently, the signaling pathways leading to a decrease in
Erk-1/2 activity and increase in p38 activity during chondro-
genesis remain to be clearly characterized. However, Erk-1/2
activities appear to be regulated by PKC, because inhibition or
down-regulation of PKC causes activation of Erk-1/2 (Fig. 8),
and the decrease in Erk-1/2 activities is correlated with the
increased expression and activation of PKC, especially PKC a
and e isoforms (Fig. 7). However, observations that inhibition
or down-regulation of PKC does not affect p38 activity (Fig. 8)
FIG. 5. p38 was required for the dif-
ferentiation of precartilage conden-
sation to cartilage nodules. Mesen-
chymes were micromass-cultured for 2 or
4 days in the presence of vehicle alone as
a control, 5 mM PD98059, or 10 mM
SB203580. The cells were stained with
PNA or Alcian blue as described under
“Experimental Procedures.” The data rep-
resent a typical experiment conducted
more than six times with similar results.
FIG. 6. Converse regulation of expression of cell adhesion molecules by Erk-1/2 and p38. Mesenchymes were cultured in the presence
of vehicle alone as a control, 5 mM PD98059, or 10 mM SB203580 for the indicated time periods. Expressions of N-cadherin, integrins a5 and b1,
and fibronectin were determined by Western blotting. The data represent a typical experiment carried out more than four times with similar
results.
FIG. 7. Erk-1/2 and p38 did not reg-
ulate expression and activation of
PKC isoforms. Mesenchymes were cul-
tured for 4 days in the presence of vehicle
alone as a control, 5 mM PD98059, or 10
mM SB203580. Expression of PKC iso-
forms was detected by Western blotting
(A). Activation of PKC isoforms was de-
termined by examining translocation of
cytosolic PKC to the membrane fraction.
c, cytosolic fraction; m, particulate mem-
brane fraction (B). The data represent a
typical experiment conducted three times
with comparable results.
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and that expression and activation of PKC isoforms are not
affected by the inhibition of p38 indicate that PKC is not
involved in the regulation of p38 activity during chondrogenesis.
Regulatory Mechanism of Chondrogenesis by Erk-1/2 and
p38—Many extracellular molecules known to regulate chon-
drogenesis exert their effects at the stages of cell proliferation
and/or precartilage condensation (5, 7, 16, 18, 33–36). In this
study, we investigated the role of p38 and Erk-1/2 in the vari-
ous regulatory steps of chondrogenesis: (i) proliferation of chon-
drogenic competent cells, (ii) precartilage condensation that
was determined by PNA staining, (iii) expression of cell adhe-
sion molecules known to be involved in precartilage condensa-
tion, and finally (iv) progression of precartilage condensation to
cartilage nodules. Our observations that inhibition of p38 and
Erk-1/2 did not affect cell proliferation (Fig. 4) and precartilage
condensation (Fig. 5) clearly indicated that the inhibitory and
stimulatory effects on chondrogenesis by the inhibition of p38
and Erk-1/2, respectively, were not caused by modulation of cell
proliferation and precartilage condensation.
In contrast to their roles in precartilage condensation, our
present results demonstrated that p38 and Erk-1/2 differen-
tially regulated the progression of precartilage condensation to
cartilage nodules (Fig. 5). Inhibition of p38 activity blocked
cartilage nodule formation demonstrating that the increase of
p38 activity during micromass culture was required for the
progression of precartilage condensation to cartilage nodules.
Because cartilage nodules were formed on day 3 and 4 cultures
as judged by the staining of PNA and Alcian blue (Fig. 5), the
time course of p38 activation, which was very weak at one day
and most active at 3 to 5-day-old cultures (Fig. 1B), was
strongly correlated to the time course of cartilage nodule for-
mation. Inhibition of the expression of cartilage-specific mole-
cules such as type II collagen and sulfated glycosaminoglycans
in the absence of p38 activity was also well consistent with the
fact that these molecules were expressed by differentiated
chondrocytes in cartilage nodules (11, 13, 15). In contrast to the
role of p38, stimulation of chondrogenesis by the inhibition of
Erk-1/2 with PD98059 did not significantly alter precartilage
condensation as well as formation of cartilage nodules (Fig. 5);
however, it enhanced expression of type II collagen and sul-
fated glycosaminoglycans (Fig. 2). Thus, it seems highly likely
that inhibition of Erk-1/2 enhances expression of cartilage-
specific molecules rather than directly modulating precartilage
condensation and cartilage nodule formation.
Our current data also demonstrated that converse regulation
of chondrogenesis by Erk-1/2 and p38 was closely associated
with converse regulation of adhesion molecules and ECM com-
ponent expression (Fig. 6), which were involved in precartilage
condensation as well as cartilage nodule formation (4, 8–10,
15). Expression patterns of the examined adhesion molecules
such as N-cadherin, integrins a5 and b1, and fibronectin at
early periods of micromass culture, i.e. in day 1 and 2 cultures
in which precartilage condensation occurred (Fig. 5), were not
significantly different whether or not Erk-1/2 and p38 activities
were blocked. However, modulation of p38 and Erk-1/2 activi-
ties regulated expression of adhesion molecules in an opposite
way at later periods of culture, i.e in day 4 and 5 cultures in
which formation of cartilage nodules and expression of carti-
lage-specific molecules occurred (Fig. 5). These results strongly
suggest that reduced expression of adhesion molecules is asso-
ciated with formation and differentiation of cartilage nodules.
Indeed, it has been shown that N-cadherin is expressed in
prechondrogenic mesenchymes and during cell condensation
but not in differentiated chondrocytes (4–7). In addition to
N-cadherin-mediated cell-cell interaction, an interaction of
mesenchymes with fibronectin via integrin a5b1 is necessary
for cell condensation to occur, and reduced expression of fi-
bronectin and its integrin a5b1 receptor following cell aggre-
gation is associated with the progression of cartilage nodule
formation (8, 9). Thus, the sustained expression of N-cadherin
and the increased expression of integrin a5b1 and fibronectin
at later stages of micromass culture upon inhibition of p38 is
closely correlated with inhibition of chondrogenesis, whereas
the accelerated decrease of expression of these molecules upon
Erk-1/2 inhibition is correlated with enhancement of chondro-
genesis. However, it remains to be more clearly elucidated
whether the modulation of the expression of adhesion mole-
cules by Erk-1/2 and p38 regulates cartilage nodule formation
and expression of cartilage-specific molecules, and also
whether modulation of chondrogenesis by the inhibition of Erk-
1/2 and p38 causes altered expression of adhesion molecules.
Although our results clearly indicate that p38 and Erk-1/2
oppositely regulate expression of adhesion molecules, the mo-
lecular mechanism of their action is not clear. One of the
possibilities is the regulation of Wnt signaling by MAP kinases.
Stott et al. (16) has recently reported that Wnt, a putative
ligand for frizzled receptor (42), is involved in chondrogenesis.
They found that transfection of Wnt-7a to cells suppressed
chondrogenic differentiation of mesenchymes. Wnt-7a did not
inhibit precartilage condensation but blocked the progression
of condensation to cartilage nodules with altered expression of
adhesion molecules, sustaining expression of N-cadherin and
wider distribution of integrins and fibronectin. Because the
effects of p38 inhibition and Wnt-7a expression are very simi-
lar, it is of interest to determine whether Wnt signaling is
conversely regulated by Erk-1/2 and p38.
While preparing our manuscript, Nakamura et al. (43) re-
FIG. 8. PKC regulated Erk-1/2, but not p38, signaling. A, mes-
enchymes were micromass-cultured for the indicated time periods in
the presence of vehicle alone as a control, 20 nM phorbol 12-myristate
13-acetate, or 1 mM Go6976. Expression of Erk-1 on day 3 cultures was
determined by Western blotting (upper panel, Erk-1). Activation of
Erk-1 was determined by Western blotting using antibodies specific to
activated Erk-1 (middle panel, p-Erk-1), and phosphorylation levels at
day 3 were quantitated by densitometry from four independent exper-
iments (lower panel). B, expression of p38 on day 3 cultures from the
cells treated with vehicle alone as a control, 20 nM phorbol 12-myristate
13-acetate, or 1 mM Go6976 was determined by Western blotting (upper
panel, p38). p38 activity was determined by immuncomplex kinase
assay using ATF-2 as a substrate (middle panel, p-ATF2), and a relative
amount of phosphorylated ATF-2 was quantitated by densitometry
(n 5 3) (lower panel).
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ported that p38 contributed to chondrogenesis of ATDC5 cells,
a clonal mouse chondrogenic cell line, induced by growth/dif-
ferentiation factor-5. They showed that growth/differentiation
factor-5 increased phosphorylation and activity of p38 dose
dependently at early time periods, i.e. within an hour, and the
inhibition of p38 activation with SB202190 suppressed expres-
sion of type II collagen and cartilage nodule formation that
occurred at day 14. They also observed that growth/differenti-
ation factor-5 induced phosphorylation of Erk-1/2 within 3 min
after treatment, and inhibition of Erk-1/2 with PD98059 en-
hanced cellular differentiation. Although the culture systems
and methods used to induce chondrogenic differentiation in
Nakamura et al. (43) and ours are quite different, the func-
tional role of MAP kinase subtypes is very similar, indicating a
common regulatory mechanism of chondrogenesis by MAP
kinases.
In summary, our present results emphasize the functional
importance of two MAP kinase subtypes, Erk-1/2 and p38, in
the regulation of chondrogenesis of limb bud mesenchymes
during micromass culture. Activities of Erk-1/2 and p38 sub-
types are oppositely varied during chondrogenesis, and the
differential activities regulate chondrogenesis oppositely at
post-precartilage condensation stages by modulating expres-
sion of adhesion molecules.
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